Emergent BioSolutions (EBS) Asset Writedowns and Impairment (2010 - 2025)

Emergent BioSolutions' Asset Writedowns and Impairment history runs 12 years deep, the most recent figure standing at $12.2 million for Q4 2025.

• In Q4 2025, Asset Writedowns and Impairment changed N/A year-over-year to $12.2 million; the TTM figure through Dec 2025 stood at $12.2 million (down 55.15% YoY), while the FY2025 annual figure was $12.2 million, down 55.15% from the prior year.
• Asset Writedowns and Impairment was $12.2 million for Q4 2025 at Emergent BioSolutions, down from $27.2 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $306.7 million in Q2 2023 to a low of $12.2 million in Q4 2025.
• Historically, Asset Writedowns and Impairment has averaged $115.4 million across 3 years, with a median of $27.2 million in 2024.
• Biggest YoY gain for Asset Writedowns and Impairment was 91.13% in 2024; the steepest drop was 91.13% in 2024.
• A 3-year view of Asset Writedowns and Impairment shows it stood at $306.7 million in 2023, then slumped by 91.13% to $27.2 million in 2024, then tumbled by 55.15% to $12.2 million in 2025.
• The last three Asset Writedowns and Impairment figures came in at $12.2 million (Q4 2025), $27.2 million (Q2 2024), and $306.7 million (Q2 2023), per Business Quant data.